Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of Tripegfilgrastim for prevention of severe neutropenia in unresectable pancreaticobiliary cancers
KCT0008772Phase 2Recruiting
- Sponsor
- Dong-A ST
- Start
- Jan 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pegfilgrastim in pancreatic cancer (PC), cholangiocarcinoma (CCA), sponsored by Dong-A ST. Started Jan 2024; status: recruiting.
02
Drugs
pegfilgrastim
03
Conditions
pancreatic cancer (PC)cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on KCT0008772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0008772.